HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

(2S,3S)- 2- ((R)- 4- (4- (2- hydroxyethoxy)phenyl)- 2,5- dioxo- imidazolidin- 1- yl)- 3- phenyl- N- (4- propionylthiazol- 2- yl)butyramide

a mitogen-activated protein kinase kinase 1/2 inhibitor for cancer therapy; structure in first source

Also Known As:

RO4927350

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - (2S,3S)-2-((R)-4-(4-(2-hydroxyethoxy)phenyl)-2,5-dioxo-imidazolidin-1-yl)-3-phenyl-N-(4-propionylthiazol-2-yl)butyramide: 1
    - Imidazoles: 150
      - (2S,3S)-2-((R)-4-(4-(2-hydroxyethoxy)phenyl)-2,5-dioxo-imidazolidin-1-yl)-3-phenyl-N-(4-propionylthiazol-2-yl)butyramide: 1
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - (2S,3S)-2-((R)-4-(4-(2-hydroxyethoxy)phenyl)-2,5-dioxo-imidazolidin-1-yl)-3-phenyl-N-(4-propionylthiazol-2-yl)butyramide: 1

Experts

1.	Daouti, Sherif: 1 article (03/2009)
2.	Fotouhi, Nader: 1 article (03/2009)
3.	He, Yang: 1 article (03/2009)
4.	Heimbrook, David: 1 article (03/2009)
5.	Higgins, Brian: 1 article (03/2009)
6.	Huby, Nicholas: 1 article (03/2009)
7.	Kolinsky, Kenneth: 1 article (03/2009)
8.	Kong, Norman: 1 article (03/2009)
9.	Li, Wen-hui: 1 article (03/2009)
10.	Niu, Huifeng: 1 article (03/2009)

Related Diseases

1.

Neoplasms (Cancer)

03/01/2009 - "Thus, RO4927350 represents a novel therapeutic modality in cancers with aberrant MAPK pathway activation."
03/01/2009 - "The unique MAPK signaling blockade mediated by RO4927350 in cancer may reduce the risk of developing drug resistance. "
03/01/2009 - "In cancer cells, high basal levels of phospho-MEK1/2 rather than phospho-ERK1/2 seem to correlate with greater sensitivity to RO4927350. "